Trial reportThorax2000
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.
Trial report in Thorax, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 7 syntheses or guidelines pooled it, 347 citations in OpenAlex.
- ADRB2 haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Pooled it
- Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.The Journal of allergy and clinical immunology · 2016Pooled it
- Regular treatment with salmeterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2008Pooled it
- Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.The Cochrane database of systematic reviews · 2007Pooled it
- The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.British journal of clinical pharmacology · 2004Pooled it
- Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.The Cochrane database of systematic reviews · 2002Pooled it
- Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment.The Cochrane database of systematic reviews · 2000Pooled it
- Trial
- A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.The pharmacogenomics journal · 2012Trial
- Trial
- Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response.Respiratory research · 2012Trial
- Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.Lancet (London, England) · 2009Trial
- beta-Adrenergic receptor polymorphisms and response to salmeterol.American journal of respiratory and critical care medicine · 2006Trial
- Trial
- Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.British journal of clinical pharmacology · 2003Trial
- Lack of association between ADRB2 (Gln27Glu) variant with susceptibility, severity and salbutamol response in South Indian asthmatics.Scientific reports · 2026Article
- Advances in the Association Between theCurrent issues in molecular biology · 2026Review
- Relationship between interleukin-13 rs20541 single nucleotide polymorphisms and therapeutic efficacy in children with asthma.The Journal of international medical research · 2020Article
- Chronic Obstructive Pulmonary Disease in America's Black Population.American journal of respiratory and critical care medicine · 2019Article
- Association of genetic variants with level of asthma control in the Arab population.Journal of asthma and allergy · 2019Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymorphisms of the beta(2) adrenoceptor influence receptor function in vitro and asthma phenotypes in vivo. However, their importance in determining responses to inhaled beta agonist treatment has not been clearly defined.
methodsIn a retrospective analysis of previously published data we have examined relationships between polymorphisms at codons 16 and 27 of the beta(2) adrenoceptor and clinical outcomes in a randomised, placebo controlled, crossover trial of regularly scheduled salbutamol and salmeterol in 115 patients with mild to moderate asthma. Genotyping was obtained for positions 16 and 27 in 108 and 107 patients, respectively. For position 16, 17 patients (16%) were homozygous Arg-Arg, 40 (37%) were heterozygous Arg-Gly, and 51 (47%) were homozygous Gly-Gly.
resultsWithin the homozygous Arg-16 group major exacerbations were more frequent during salbutamol treatment than with placebo (1.91 (95% CI 1.07 to 3.12) per year versus 0.81 (95% CI 0.28 to 1.66) per year; p = 0.005). No significant treatment related differences occurred for heterozygous Arg-Gly patients (salbutamol 0.11 (95% CI 0.01 to 0.40), placebo 0.54 (95% CI 0.26 to 1.00) exacerbations per year) or homozygous Gly-16 patients (salbutamol 0.38 (95% CI 0.17 to 0.73), placebo 0.30 (95% CI 0.12 to 0.61) exacerbations per year). No adverse changes occurred for any position 16 subgroup with salmeterol. There was no significant relationship between position 27 genotypes and treatment related outcomes.
conclusionHomozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting beta(2) agonist salbutamol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.